$1.52 +0.08 (5.56%)

Calidi Biotherapeutics, Inc. (CLDI)

Calidi Biotherapeutics, Inc. (CLDI) is a biotechnology company focused on developing advanced cell-based immunotherapies for cancer and infectious diseases. The company leverages proprietary platform technologies, including its tumor-targeting and immune-activating cell systems, to create innovative treatments aimed at improving patient outcomes.

🚫 Calidi Biotherapeutics, Inc. does not pay dividends

Company News

Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option
GlobeNewswire Inc. • Calidi Biotherapeutics • August 21, 2025

Calidi Biotherapeutics completed a public offering, raising $6.9 million by selling common stock units and pre-funded warrant units, with Ladenburg Thalmann & Co. Inc. acting as sole book-running manager.

Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
Benzinga • Prnewswire • July 9, 2025

Calidi Biotherapeutics is developing a groundbreaking genetic medicine platform using engineered viruses to precisely target and treat metastatic cancers, with promising preclinical data presented at AACR and ASCO conferences.

VRTXIBRXCRSPCTMX
Calidi Biotherapeutics announces 1-for-10 reverse stock split - Investing.com
Investing.com • Natashya Angelica • July 15, 2024

Calidi Biotherapeutics, a biotechnology company, announced a 1-for-10 reverse stock split to enhance shareholder value. The move aims to increase the per-share trading price and potentially satisfy listing requirements.